Vertex Pharmaceuticals Launches Suzetrigine as a First-in-Class Pain Signal Inhibitor at ASA Meeting

Vertex Pharmaceuticals will present pivotal Phase 3 data on suzetrigine, a novel oral NaV1.8 pain signal inhibitor aimed at treating moderate-to-severe acute pain, at the American Society of Anesthesiologists Annual Meeting from October 18-22, 2024. This presentation marks the first showing of promising Phase 3 trial results in the medical community, highlighting suzetrigine's potential to revolutionize non-opioid pain management.